Répertoire du corps professoral

Financements des 2 dernières années

FRQS-Réseau de recherche sur le cancer - Axe de recherche et de banques de tissus et de données en cancers solides (BTD)
Programme: Réseaux thématiques de recherche
Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2007 au 31 mars 2023

Encadrements terminés dans les 5 dernières années

Sadia Mehdi, Doctorat en biologie cellulaire et moléculaire

Publications des 5 dernières années

LY75 Ablation Mediates Mesenchymal-Epithelial Transition (MET) in Epithelial Ovarian Cancer (EOC) Cells Associated with DNA Methylation Alterations and Suppression of the Wnt/β-Catenin Pathway International Journal of Molecular Sciences, 2020/03. Sadia Mehdi, Magdalena Bachvarova, Marie-Pier Scott-Boyer, Arnaud Droit, Dimcho Bachvarov. DOI 10.3390/ijms21051848

Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer. PloS one, 2019/06. Furrer D, Grégoire J, Turcotte S, Plante M, Bachvarov D, Trudel D, Têtu B, Douville P, Bairati I. DOI 10.1371/journal.pone.0218621

The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression. International journal of molecular sciences, 2019/05. Sheta R, Bachvarova M, Macdonald E, Gobeil S, Vanderhyden B, Bachvarov D. DOI 10.3390/ijms20092264

Proffered papers and posters presented at the Seventh International Symposium on Hereditary Breast and Ovarian Cancer—BRCA: From the Personal to the Population: Presented by the Hereditary Breast and Ovarian Cancer Foundation in collaboration with the Program in Cancer Genetics, McGill University; Centre Mont-Royal, Montreal, QC; 8–11 May 2018. Current oncology (Toronto, Ont.), 2018/06. DOI 10.3747/co.25.4243

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC cancer, 2018/03. Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, Mes-Masson AM. DOI 10.1186/s12885-018-4242-8

Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy Journal of Translational Medicine, 2020/12. Razan Sheta, Magdalena Bachvarova, Marie Plante, Marie-Claude Renaud, Alexandra Sebastianelli, Jean Gregoire, Jamilet Miranda Navarro, Ricardo Bringas Perez, Jean-Yves Masson, Dimcho Bachvarov. DOI 10.1186/s12967-020-02613-4

Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer. Pathology, research and practice, 2019/03. Trudel D, Avarvarei LM, Orain M, Turcotte S, Plante M, Grégoire J, Kappelhoff R, Labbé DP, Bachvarov D, Têtu B, Overall CM, Bairati I. DOI 10.1016/j.prp.2019.02.019